PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-4.58%
Negative net income growth while AVGO stands at 0.00%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
1.96%
D&A growth of 1.96% while AVGO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
-1014.29%
Negative yoy deferred tax while AVGO stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
-100.00%
Negative yoy SBC while AVGO is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
167.37%
Working capital change of 167.37% while AVGO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might affect near-term cash flow.
No Data
No Data available this quarter, please select a different quarter.
204.11%
Inventory growth of 204.11% while AVGO is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
No Data
No Data available this quarter, please select a different quarter.
158.55%
Growth of 158.55% while AVGO is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
980.00%
Growth of 980.00% while AVGO is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might reflect intangible expansions or partial write-offs.
102.70%
CFO growth of 102.70% while AVGO is zero at 0.00%. Bruce Berkowitz would see a modest edge that could widen if cost discipline remains strong.
27.04%
CapEx growth of 27.04% while AVGO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-27.03%
We reduce yoy sales while AVGO is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
100.00%
Growth of 100.00% while AVGO is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
34.25%
We expand invests by 34.25% while AVGO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-66.29%
Negative yoy issuance while AVGO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
0.92%
Buyback growth of 0.92% while AVGO is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.